Aromatase Inhibitors Clinical Trials

3 actively recruiting trials

▲ +2 trials since June 2026

Also known as: ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE

Pipeline

Phase 2: 3

Top Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University2
Centre Leon Berard1

Indications

Cancer3
HR+/HER2- Early Breast Cancer2
Breast Cancer2
Low Grade Endometrial Stromal Sarcoma1

Other3 trials

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Phase 2

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Phase 2

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.